Pancreatic Endocrine Toxicity | InSphero

Assess drug-induced beta-cell injury in long-lived, robust 3D islet models

Decreased β-cell mass is an important factor in the pathogenesis of type 2 diabetes and thus raises a concern regarding the application of drugs potentially harmful to the remaining beta cells (1). Several stimuli, such as increased oxidative stress, ER-stress, hypoxia and cytokine induction, are known to cause beta-cell apoptosis or de-differentiation, and have been shown to impair beta-cell functionality (2). Drugs stimulating these effects might harm beta-cell functionality. In addition, drugs designed to target beta-cells directly might cause impairment of their viability and functionality after long-term treatment. With the robust functionality over more than 28 days in culture, 3D InSight™ Islet Microtissues enable studies to determine the effect of prolonged drug exposure on islet viability and functionality.

  • Choose your model (human or rat)
  • Select your desired endpoints from the menu below
  • Work with our services team to design a study plan we’ll implement for you using 3D optimized assays

References

  • Seino & Bell, 2008, Pancreatic Beta Cell in Health and Disease, Springer
  • Kitamura, 2013, Nature Reviews Endocrinology
Toxicity mechanismCellular indicator
Cytotoxicity
  • ATP-content
β-cell function/toxicity
  • Insulin content
  • Insulin secretion (chronic and basal)
  • Glucose-stimulated Insulin Secretion (GSIS)

Related Services

Diabetes & NASH Drug Discovery

Microtissues and Kits

Islet

Request Additional Resources

Brochure: Human Islet Microtissues

Request

Find out how you can assess drug-induced

islet toxicity with greater certainty.

Get Started